{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:50:16Z","timestamp":1790700616205,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The metzincin family of metalloproteinases and the tissue inhibitors of metalloproteinases (TIMPs) are essential proteins required for biological processes during cancer progression. This study aimed to determine the role of TIMP-2 in ovarian cancer progression and chemoresistance by reducing TIMP-2 expression in vitro in Fallopian tube secretory epithelial (FT282) and ovarian cancer (JHOS2 and OVCAR4) cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>FT282, JHOS2 and OVCAR4 cells were transiently transfected with either single or pooled TIMP-2 siRNAs. The expression of different genes after TIMP-2 knock down (T2-KD) or in response to chemotherapy was determined at the mRNA level by quantitative real time PCR (qRT-PCR) and at the protein level by immunofluorescence. Sensitivity of the cell lines in response to chemotherapy after TIMP-2 knock down was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-Ethynyl-2\u2032-deoxyuridine (EdU) assays. Cell invasion in response to TIMP-2 knockdown was determined by xCELLigence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty to 90 % knock down of TIMP-2 expression was confirmed in FT282, OVCAR4 and JHOS2 cell lines at the mRNA and protein levels. TIMP-2 knock down did not change the mRNA expression of TIMP-1 or TIMP-3. However, a significant downregulation of MMP-2 in T2-KD cells occurred at both the protein and activation levels, compared to Control (Cont; scrambled siRNA) and Parental cells (P, transfection reagent only). In contrast, membrane bound MT1-MMP protein levels were significantly upregulated in T2-KD compared to Cont and P cells. T2-KD cells exhibited enhanced proliferation and increased sensitivity to cisplatin and paclitaxel treatments. Enhanced invasion was observed in the T2-KD-JOSH2 and OVCAR4 cells but not in T2-KD-FT282 cells. Treatment with cisplatin or paclitaxel significantly elevated the expression of TIMP-2 in Cont cells but not in T2-KD cells, consistent with significantly elevated expression of chemoresistance and CSC markers and activation of STAT3. Furthermore, a potent inhibitor of STAT3 activation, Momelotinib, suppressed chemotherapy-induced activation of P-STAT3 in OVCAR4 cells with concomitant reductions in the expression of chemoresistance genes and CSC markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The above results suggest that TIMP-2 may have a novel role in ovarian cancer proliferation, invasion and chemoresistance.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07274-6","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:02:54Z","timestamp":1602010974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells"],"prefix":"10.1186","volume":"20","author":[{"given":"Ruth M.","family":"Escalona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Bilandzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Western","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Kadife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kannourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jock K.","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-5053","authenticated-orcid":false,"given":"Nuzhat","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"4","key":"7274_CR1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"7274_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","volume":"32","author":"AE Freimund","year":"2018","unstructured":"Freimund AE, Beach JA, Christie EL, Bowtell DDL. Mechanisms of drug resistance in high-grade serous ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):983\u201396.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"7274_CR3","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1002\/jcp.26289","volume":"233","author":"L Norouzi-Barough","year":"2018","unstructured":"Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S, Salehi R. Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol. 2018;233(6):4546\u201362.","journal-title":"J Cell Physiol"},{"key":"7274_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semcancer.2018.10.002","volume":"53","author":"N Ahmed","year":"2018","unstructured":"Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol. 2018;53:265\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"7274_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrm2125","volume":"8","author":"A Page-McCaw","year":"2007","unstructured":"Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221\u201333.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7274_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2015.04.005","volume":"44-46","author":"SS Apte","year":"2015","unstructured":"Apte SS, Parks WC. Metalloproteinases: a parade of functions in matrix biology and an outlook for the future. Matrix Biol. 2015;44-46:1\u20136.","journal-title":"Matrix Biol"},{"issue":"1","key":"7274_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10555-006-7893-x","volume":"25","author":"R Chirco","year":"2006","unstructured":"Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25(1):99\u2013113.","journal-title":"Cancer Metastasis Rev"},{"key":"7274_CR8","doi-asserted-by":"crossref","unstructured":"Escalona RM, Chan E, Kannourakis G, Findlay JK, Ahmed N. The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. Int J Mol Sci. 2018;19(2):450.","DOI":"10.3390\/ijms19020450"},{"issue":"52","key":"7274_CR9","doi-asserted-by":"publisher","first-page":"41415","DOI":"10.1074\/jbc.M006871200","volume":"275","author":"M Toth","year":"2000","unstructured":"Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, Cher ML, et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem. 2000;275(52):41415\u201323.","journal-title":"J Biol Chem"},{"issue":"7","key":"7274_CR10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1541-7786.MCR-09-0523","volume":"8","author":"Q Shen","year":"2010","unstructured":"Shen Q, Lee ES, Pitts RL, Wu MH, Yuan SY. Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells. Mol Cancer Res. 2010;8(7):939\u201351.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"7274_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbamcr.2010.01.003","volume":"1803","author":"K Brew","year":"2010","unstructured":"Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55\u201371.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"7274_CR12","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1074\/jbc.M008157200","volume":"276","author":"SE Hoegy","year":"2001","unstructured":"Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem. 2001;276(5):3203\u201314.","journal-title":"J Biol Chem"},{"issue":"53","key":"7274_CR13","doi-asserted-by":"publisher","first-page":"41886","DOI":"10.1074\/jbc.M110.166439","volume":"285","author":"CA Fernandez","year":"2010","unstructured":"Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem. 2010;285(53):41886\u201395.","journal-title":"J Biol Chem"},{"issue":"2","key":"7274_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(03)00551-8","volume":"114","author":"DW Seo","year":"2003","unstructured":"Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114(2):171\u201380.","journal-title":"Cell"},{"key":"7274_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.isci.2018.02.004","volume":"1","author":"J Sanchez-Pozo","year":"2018","unstructured":"Sanchez-Pozo J, Baker-Williams AJ, Woodford MR, Bullard R, Wei B, Mollapour M, Stetler-Stevenson WG, Bratslavsky G, Bourboulia D. Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity. iScience. 2018;1:87\u201396.","journal-title":"iScience"},{"key":"7274_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.mam.2013.06.002","volume":"39","author":"N Ahmed","year":"2014","unstructured":"Ahmed N, Abubaker K, Findlay JK. Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets. Mol Aspects Med. 2014;39:110\u201325.","journal-title":"Mol Aspects Med"},{"issue":"11","key":"7274_CR17","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311\u201320.","journal-title":"Cancer Res"},{"key":"7274_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fonc.2014.00075","volume":"4","author":"K Abubaker","year":"2014","unstructured":"Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW, Findlay JK, Ahmed N. Targeted disruption of the JAK2\/STAT3 pathway in combination with systemic Administration of Paclitaxel Inhibits the priming of ovarian Cancer stem cells leading to a reduced tumor burden. Front Oncol. 2014;4:75.","journal-title":"Front Oncol"},{"key":"7274_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/1471-2407-14-317","volume":"14","author":"K Abubaker","year":"2014","unstructured":"Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N. Inhibition of the JAK2\/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014;14:317.","journal-title":"BMC Cancer"},{"key":"7274_CR20","doi-asserted-by":"crossref","unstructured":"Jin W. Role of JAK\/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. Cells. 2020;9(1):217.","DOI":"10.3390\/cells9010217"},{"issue":"3","key":"7274_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","volume":"18","author":"AD Steg","year":"2012","unstructured":"Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 2012;18(3):869\u201381.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7274_CR22","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/stem.185","volume":"27","author":"MM Sherry","year":"2009","unstructured":"Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27(10):2383\u201392.","journal-title":"Stem Cells"},{"issue":"12","key":"7274_CR23","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/cdd.2011.77","volume":"18","author":"JR Matthews","year":"2011","unstructured":"Matthews JR, Sansom OJ, Clarke AR. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ. 2011;18(12):1934\u201343.","journal-title":"Cell Death Differ"},{"issue":"12","key":"7274_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052608","volume":"7","author":"AD Staniszewska","year":"2012","unstructured":"Staniszewska AD, Pensa S, Caffarel MM, Anderson LH, Poli V, Watson CJ. Stat3 is required to maintain the full differentiation potential of mammary stem cells and the proliferative potential of mammary luminal progenitors. PLoS One. 2012;7(12):e52608.","journal-title":"PLoS One"},{"issue":"11","key":"7274_CR25","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1002\/cncr.22293","volume":"107","author":"DG Rosen","year":"2006","unstructured":"Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006;107(11):2730\u201340.","journal-title":"Cancer"},{"issue":"8","key":"7274_CR26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","volume":"19","author":"A Quintas-Cardama","year":"2013","unstructured":"Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933\u201340.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7274_CR27","first-page":"131","volume":"12","author":"K Yamada","year":"1999","unstructured":"Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary. Hum Cell. 1999;12(3):131\u20138.","journal-title":"Hum Cell"},{"issue":"1","key":"7274_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1101\/gr.108803.110","volume":"21","author":"N Matsumura","year":"2011","unstructured":"Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 2011;21(1):74\u201382.","journal-title":"Genome Res"},{"issue":"2","key":"7274_CR29","first-page":"751","volume":"45","author":"R Pirker","year":"1985","unstructured":"Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Willingham MC, Pastan I. Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res. 1985;45(2):751\u20137.","journal-title":"Cancer Res"},{"issue":"9","key":"7274_CR30","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/nprot.2012.097","volume":"7","author":"AM Karst","year":"2012","unstructured":"Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc. 2012;7(9):1755\u201364.","journal-title":"Nat Protoc"},{"issue":"24","key":"7274_CR31","doi-asserted-by":"publisher","first-page":"16599","DOI":"10.18632\/oncotarget.24615","volume":"9","author":"E Chan","year":"2018","unstructured":"Chan E, Luwor R, Burns C, Kannourakis G, Findlay JK, Ahmed N. Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget. 2018;9(24):16599\u2013618.","journal-title":"Oncotarget"},{"key":"7274_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1477-3163-6-11","volume":"6","author":"K Shield","year":"2007","unstructured":"Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;6:11.","journal-title":"J Carcinog"},{"issue":"3","key":"7274_CR33","first-page":"209","volume":"11","author":"MJ Murnane","year":"1997","unstructured":"Murnane MJ, Shuja S, Del Re E, Cai J, Iacobuzio-Donahue C, Klepeis V. Characterizing human colorectal carcinomas by proteolytic profile. In Vivo. 1997;11(3):209\u201316.","journal-title":"In Vivo"},{"key":"7274_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1756-0500-6-168","volume":"6","author":"SI Wakeling","year":"2013","unstructured":"Wakeling SI, Miles DC, Western PS. Identifying disruptors of male germ cell development by small molecule screening in ex vivo gonad cultures. BMC Res Notes. 2013;6:168.","journal-title":"BMC Res Notes"},{"key":"7274_CR35","doi-asserted-by":"crossref","unstructured":"Bilandzic M, Stenvers KL. Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time. J Visualized Experiments. 2014;87(E51655):1-6.","DOI":"10.3791\/51655"},{"issue":"3","key":"7274_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1095\/biolreprod.112.102194","volume":"88","author":"MA Sarraj","year":"2013","unstructured":"Sarraj MA, Escalona RM, Western P, Findlay JK, Stenvers KL. Effects of TGFbeta2 on wild-type and Tgfbr3 knockout mouse fetal testis. Biol Reprod. 2013;88(3):66.","journal-title":"Biol Reprod"},{"issue":"4","key":"7274_CR37","first-page":"2519","volume":"19","author":"B Li","year":"2019","unstructured":"Li B, Lou G, Zhou J. MT1MMP promotes the proliferation and invasion of gastric carcinoma cells via regulating vimentin and Ecadherin. Mol Med Rep. 2019;19(4):2519\u201326.","journal-title":"Mol Med Rep"},{"issue":"2","key":"7274_CR38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7555\/JBR.31.20160124","volume":"32","author":"A Sulaiman","year":"2018","unstructured":"Sulaiman A, Yao ZM, Wang LS. Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression. J Biomed Res. 2018;32(2):81\u201390.","journal-title":"J Biomed Res"},{"issue":"3","key":"7274_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1042\/BST20180363","volume":"47","author":"V Gifford","year":"2019","unstructured":"Gifford V, Itoh Y. MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms. Biochem Soc Trans. 2019;47(3):811\u201326.","journal-title":"Biochem Soc Trans"},{"issue":"1\u20132","key":"7274_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11010-016-2693-2","volume":"416","author":"S Sur","year":"2016","unstructured":"Sur S, Agrawal DK. Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem. 2016;416(1\u20132):33\u201346.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"7274_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"C Gialeli","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16\u201327.","journal-title":"FEBS J"},{"issue":"1","key":"7274_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbamcr.2009.04.003","volume":"1803","author":"C Tallant","year":"2010","unstructured":"Tallant C, Marrero A, Gomis-Ruth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta. 2010;1803(1):20\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"7274_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/03008207.2013.867339","volume":"55","author":"WG Stetler-Stevenson","year":"2014","unstructured":"Stetler-Stevenson WG, Gavil NV. Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic. Connect Tissue Res. 2014;55(1):13\u20139.","journal-title":"Connect Tissue Res"},{"issue":"5","key":"7274_CR44","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.ajpath.2011.07.035","volume":"179","author":"D Bourboulia","year":"2011","unstructured":"Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol. 2011;179(5):2589\u2013600.","journal-title":"Am J Pathol"},{"issue":"7","key":"7274_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1369\/0022155412446978","volume":"60","author":"A Halon","year":"2012","unstructured":"Halon A, Nowak-Markwitz E, Donizy P, Matkowski R, Maciejczyk A, Gansukh T, Gyorffy B, Spaczynski M, Zabel M, Lage H, et al. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J Histochem Cytochem. 2012;60(7):491\u2013501.","journal-title":"J Histochem Cytochem"},{"issue":"1\u20132","key":"7274_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0303-7207(01)00709-2","volume":"187","author":"B Davidson","year":"2002","unstructured":"Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 2002;187(1\u20132):39\u201345.","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"7274_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/molehr\/gag074","volume":"9","author":"T Okamoto","year":"2003","unstructured":"Okamoto T, Niu R, Yamada S. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary. Mol Hum Reprod. 2003;9(10):569\u201375.","journal-title":"Mol Hum Reprod"},{"issue":"4","key":"7274_CR48","first-page":"673","volume":"17","author":"K Sakata","year":"2000","unstructured":"Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17(4):673\u201381.","journal-title":"Int J Oncol"},{"issue":"1","key":"7274_CR49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12885-017-3573-1","volume":"17","author":"T Ohsuga","year":"2017","unstructured":"Ohsuga T, Yamaguchi K, Kido A, Murakami R, Abiko K, Hamanishi J, Kondoh E, Baba T, Konishi I, Matsumura N. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. BMC Cancer. 2017;17(1):580.","journal-title":"BMC Cancer"},{"issue":"16","key":"7274_CR50","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198\u2013208.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7274_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.18632\/oncotarget.801","volume":"4","author":"D Bourboulia","year":"2013","unstructured":"Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin\/beta-catenin complex expression in A549 lung cancer cells. Oncotarget. 2013;4(1):166\u201376.","journal-title":"Oncotarget"},{"issue":"17","key":"7274_CR52","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","volume":"69","author":"NM Moss","year":"2009","unstructured":"Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res. 2009;69(17):7121\u20139.","journal-title":"Cancer Res"},{"key":"7274_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fonc.2013.00097","volume":"3","author":"MP Steinkamp","year":"2013","unstructured":"Steinkamp MP, Winner KK, Davies S, Muller C, Zhang Y, Hoffman RM, Shirinifard A, Moses M, Jiang Y, Wilson BS. Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models. Front Oncol. 2013;3:97.","journal-title":"Front Oncol"},{"issue":"27","key":"7274_CR54","doi-asserted-by":"publisher","first-page":"24833","DOI":"10.1074\/jbc.M005631200","volume":"276","author":"SM Ellerbroek","year":"2001","unstructured":"Ellerbroek SM, Wu YI, Overall CM, Stack MS. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem. 2001;276(27):24833\u201342.","journal-title":"J Biol Chem"},{"issue":"10","key":"7274_CR55","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1515\/hsz-2014-0155","volume":"395","author":"L Bruney","year":"2014","unstructured":"Bruney L, Conley KC, Moss NM, Liu Y, Stack MS. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16\/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium. Biol Chem. 2014;395(10):1221\u201331.","journal-title":"Biol Chem"},{"issue":"2","key":"7274_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.gene.2016.05.025","volume":"590","author":"Y Yin","year":"2016","unstructured":"Yin Y, Dou X, Duan S, Zhang L, Xu Q, Li H, Li D. Downregulation of cell division cycle 25 homolog C reduces the radiosensitivity and proliferation activity of esophageal squamous cell carcinoma. Gene. 2016;590(2):244\u20139.","journal-title":"Gene"},{"issue":"2","key":"7274_CR57","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B","volume":"75","author":"P Valente","year":"1998","unstructured":"Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998;75(2):246\u201353.","journal-title":"Int J Cancer"},{"issue":"6","key":"7274_CR58","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1172\/JCI1584","volume":"101","author":"AH Baker","year":"1998","unstructured":"Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, \u22122, or \u22123 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998;101(6):1478\u201387.","journal-title":"J Clin Invest"},{"issue":"6","key":"7274_CR59","first-page":"4831","volume":"18","author":"A Chen","year":"2018","unstructured":"Chen A, Liu S, Lu X, Wei L, Chen Y. Inhibition of microRNA939 suppresses the development of human nonsmall cell lung cancer via the upregulation of tissue inhibitor of metalloproteinases 2. Mol Med Rep. 2018;18(6):4831\u20138.","journal-title":"Mol Med Rep"},{"key":"7274_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-12-24","volume":"12","author":"K Abubaker","year":"2013","unstructured":"Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer. 2013;12:24.","journal-title":"Mol Cancer"},{"issue":"8","key":"7274_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973\u20139.","journal-title":"Nat Cell Biol"},{"key":"7274_CR62","doi-asserted-by":"crossref","unstructured":"Xiao W, Wang L, Howard J, Kolhe R, Rojiani AM, Rojiani MV. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers (Basel). 2019;11(8):1184.","DOI":"10.3390\/cancers11081184"},{"issue":"1","key":"7274_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2045-3701-1-14","volume":"1","author":"H Wang","year":"2011","unstructured":"Wang H, Lafdil F, Wang L, Yin S, Feng D, Gao B. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci. 2011;1(1):14.","journal-title":"Cell Biosci"},{"issue":"5","key":"7274_CR64","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1007\/s12032-012-0252-6","volume":"29","author":"AK Guddati","year":"2012","unstructured":"Guddati AK. Ovarian cancer stem cells: elusive targets for chemotherapy. Med Oncol. 2012;29(5):3400\u20138.","journal-title":"Med Oncol"},{"issue":"9","key":"7274_CR65","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/ijc.23732","volume":"123","author":"V Levina","year":"2008","unstructured":"Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer. 2008;123(9):2031\u201340.","journal-title":"Int J Cancer"},{"issue":"2","key":"7274_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358(2):100\u20136.","journal-title":"Cancer Lett"},{"key":"7274_CR67","doi-asserted-by":"crossref","unstructured":"Kareva I. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. Int J Mol Sci. 2017;18(10):2134.","DOI":"10.3390\/ijms18102134"},{"issue":"25","key":"7274_CR68","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.1074\/jbc.M800109200","volume":"283","author":"LY Bourguignon","year":"2008","unstructured":"Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283(25):17635\u201351.","journal-title":"J Biol Chem"},{"key":"7274_CR69","doi-asserted-by":"publisher","first-page":"30061","DOI":"10.1038\/srep30061","volume":"6","author":"N Ahmed","year":"2016","unstructured":"Ahmed N, Greening D, Samardzija C, Escalona RM, Chen M, Findlay JK, Kannourakis G. Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Sci Rep. 2016;6:30061.","journal-title":"Sci Rep"},{"issue":"17","key":"7274_CR70","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-06-0861","volume":"12","author":"Z Duan","year":"2006","unstructured":"Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12(17):5055\u201363.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"7274_CR71","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/pin.12019","volume":"62","author":"K Okudela","year":"2012","unstructured":"Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma--their prognostic significance. Pathol Int. 2012;62(12):792\u2013801.","journal-title":"Pathol Int"},{"issue":"1","key":"7274_CR72","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6604794","volume":"100","author":"M Colomiere","year":"2009","unstructured":"Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2\/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100(1):134\u201344.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T04:33:32Z","timestamp":1696826012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7274"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07274-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Research and Ethics Committee of Royal Women\u2019s Hospital (Approval#09\/09), Melbourne, Australia. Human ovarian tumour samples were acquired from patients after obtaining written patient information consent as indicated in the Ethics Approval (09\/09).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen the contents in the manuscript and agree for its publication. The authors also agree with the order of authorship in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"960"}}